Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report

Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small c...

Descripción completa

Detalles Bibliográficos
Autores principales: XUE, XINYING, XUE, QINGLIANG, LIU, YUXIA, PAN, LEI, WANG, KAIFEI, ZHANG, LINA, WANG, NA, YANG, BING, WANG, JIANXIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678659/
https://www.ncbi.nlm.nih.gov/pubmed/23761825
http://dx.doi.org/10.3892/ol.2013.1212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678659/
https://www.ncbi.nlm.nih.gov/pubmed/23761825
http://dx.doi.org/10.3892/ol.2013.1212

Ejemplares similares